Waitr - WTRH Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Waitr in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" WTRH shares.
View WTRH analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1-year price targets for Waitr's shares. Their WTRH share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 436.8% from the stock's current price.
View analysts price targets for WTRH or view top-rated stocks among Wall Street analysts.

Waitr's stock was trading at $0.74 at the beginning of 2022. Since then, WTRH stock has decreased by 49.6% and is now trading at $0.3726.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our WTRH earnings forecast.

Waitr Holdings Inc. (NASDAQ:WTRH) posted its quarterly earnings data on Monday, August, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.06. The company had revenue of $49.17 million for the quarter, compared to analysts' expectations of $50.30 million. Waitr had a negative net margin of 57.15% and a negative trailing twelve-month return on equity of 28.55%.

16 employees have rated Waitr Chief Executive Officer Carl Grimstad on Glassdoor.com. Carl Grimstad has an approval rating of 58% among the company's employees. This puts Carl Grimstad in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waitr investors own include Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novan (NOVN), DHT (DHT), iBio (IBIO), OPKO Health (OPK) and Zosano Pharma (ZSAN).

Waitr trades on the NASDAQ under the ticker symbol "WTRH."

Waitr's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.51%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Buford H Ortale, Damon E Schramm, Jonathan Green, Joseph Stough, Steven L Scheinthal, Steven L Scheinthal, Tilman J Fertitta and Timothy Alan Newton.
View institutional ownership trends.

Shares of WTRH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WTRH stock can currently be purchased for approximately $0.37.

Waitr (NASDAQ:WTRH) has a market capitalization of $71.08 million and generates $182.19 million in revenue each year. The company earns $-5,230,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

The company employs 1,034 workers across the globe.

Waitr's mailing address is 214 Jefferson Street Suite 200, Lafayette LA, 70501. The official website for the company is www.waitrapp.com. The company can be reached via phone at (337) 534-6881 or via email at waitrir@icrinc.com.